Case number 1:21-cv-01407
Novartis Pharmaceuticals Corporation v. Aurobindo Pharma USA Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 21, 2023 | 67 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment)(nms) (Entered: 04/21/2023) (Consent Judgment) (5) |
| Apr 21, 2023 | 67 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment)(nms) (Entered: 04/21/2023) (Main Document) (1) |
| Apr 21, 2023 | 66 | REDACTED VERSION of 62 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/21/2023 (nms). (Entered: 04/21/2023) (5) |
| Apr 11, 2023 | 65 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Markman hearing scheduled for 4/14/2023, regarding U.S. Patent No. 11,058,667. (Silver, Daniel) Modified on 4/12/2023 (nms). (Entered: 04/11/2023) (2) |
| Apr 11, 2023 | 64 | [SEALED] Consent Judgment and Order of Injunction between Plaintiff and Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc.. Signed by Judge Richard G. Andrews on 4/11/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:21-cv-01407-RGA(nms) (Entered: 04/11/2023) (0) |
| Apr 11, 2023 | 63 | NOTICE OF SERVICE of copies of (i) Defendants' Second Set of Common Interrogatories to Novartis (Nos. 10-13); and, (ii) Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56) to Novartis filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 04/11/2023) (3) |
| Apr 11, 2023 | 62 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/11/2023 (nms). (Entered: 04/11/2023) (0) |
| Apr 7, 2023 | 61 | REDACTED VERSION of 57 Appendix, Volume 2, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/7/2023 (nms). (Entered: 04/07/2023) (20) |
| Apr 5, 2023 | 60 | MARKMAN HEARING ORDER: The Joint Claim Construction Brief (D.I. 974 ) is UNSEALED. The argument at the Markman Hearing on April 14, 2023, is limited to ten minutes per side. For the first disputed term, there appears to be a definition at '667 Patent 16:20-24. I think that is what each side means by their proposals. In any event, the parties' proposals are STRUCK. If either party thinks the above-referenced definition is inadequate in some regard, that party is to propose a construction including the definition and any additional language that the party argues is necessary. "Specific," as already proposed by Defendants, is rejected. I note that "crystalline," as proposed by Defendants, seems to be agreed upon by Novartis. (D.I. 974 at 31). But I am unclear whether it is necessary. Any proposed constructions should be submitted by 5 p.m. Tuesday, April 11, 2023. The proposed construction and any justification for it shall be set forth in 250 words or less. For the second disputed term, there also appears to be a definition, this time at '667 Patent 5:22-35. The parties only have one disagreement (in addition to the one addressed above in 3), which is Defendants' proposed negative limitation. As I understand Novartis's position, there is no dispute because part (a) of the definition includes exactly one "complex"-the one described at '667 Patent 16:20-24-and part (b) includes no complexes at all. If Novartis confirms that I understand its position correctly, then I also agree with Novartis that adding a negative limitation is pointless. Novartis should advise whether it confirms the above no later than 5 p.m. Tuesday, April 11, 2023. Signed by Judge Richard G. Andrews on 4/5/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/05/2023) (2) |
| Mar 31, 2023 | 58 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit O-V) (30) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit A-K) (30) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 5 of 5) (13) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 4 of 5) (30) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 3 of 5) (30) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 2 of 5) (30) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 1 of 5) (30) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 1) (16) |
| Mar 31, 2023 | 59 | Joint Motion for Claim Construction - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/3/2023 (nms). (Entered: 03/31/2023) (8) |
| Mar 31, 2023 | 58 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 57 | [SEALED] APPENDIX, Volume 2 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits L-N)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (0) |
| Mar 31, 2023 | 56 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 55 | Joint Claim Construction Brief regarding U.S. Patent No. 11,058,667, filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/31/2023 (nms). Modified on 4/5/2023 (nms). (Entered: 03/31/2023) (30) |
| Mar 24, 2023 | 54 | NOTICE OF SERVICE of (i) Defendants' Sur-Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 with Exs. U and V [HIGHLY CONFIDENTIAL-ATTORNEYS EYES ONLY]; and, (ii) a replacement version of Ex. H, which was previously served on February 10, 2023 with Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/24/2023) (3) |
| Mar 22, 2023 | 53 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 6, 2023 | 52 | NOTICE OF SERVICE of Novartis's Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/06/2023) (7) |
| Mar 6, 2023 | 51 | NOTICE OF SERVICE of Defendants' Objections and Responses to Novartis's First Set of Common Interrogatories (No. 1) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/06/2023) (5) |
| Feb 10, 2023 | 50 | NOTICE OF SERVICE of Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 02/10/2023) (3) |
| Feb 2, 2023 | 49 | NOTICE OF SERVICE of Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/02/2023) (7) |
| Jan 24, 2023 | 48 | MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz and Michael P. Hogan - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Myer, R.) (Entered: 01/24/2023) (6) |
| Jan 23, 2023 | 47 | NOTICE OF SERVICE of Novartis's Opening Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/23/2023) (7) |
| Jan 19, 2023 | 46 | NOTICE OF SUBSTITUTION OF COUNSEL re Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.: Entry of appearance of attorney R. Touhey Myer. Attorney Kenneth L. Dorsney, Cortlan S. Hitch terminated. (Myer, R.) (Entered: 01/19/2023) (3) |
| Dec 30, 2022 | 45 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Appendix) (30) |
| Dec 30, 2022 | 45 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Main Document) (13) |
| Dec 30, 2022 | 44 | [SEALED] ORDER Granting (D.I. 932 in 20-md-2930-RGA; D.I. 128 in 21-cv-1330-RGA; D.I. 42 in 21-cv-1407-RGA) STIPULATION to Extend Time. Signed by Judge Richard G. Andrews on 12/30/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01407-RGA(nms) (Entered: 12/30/2022) (0) |
| Dec 21, 2022 | 43 | REDACTED VERSION of 42 STIPULATION to Extend the Deadline to Substantially Complete Document Production to February 17, 2023, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/21/2022 (nms). (Entered: 12/21/2022) (3) |
| Dec 21, 2022 | 42 | [SEALED] STIPULATION to Extend the Deadline to Substantially Complete Document Production to February 17, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/21/2022 (nms). (Entered: 12/21/2022) (0) |
| Dec 15, 2022 | 41 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Evidence for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 15, 2022 | 40 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for Production (Nos. 1-44) for the '667 patent, and (2) Novartis's Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9) for the '667 patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 6, 2022 | 39 | STIPULATION TO EXTEND TIME the Deadline to Substantially Complete Document Production to January 18, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/06/2022) (7) |
| Nov 14, 2022 | 38 | NOTICE OF SERVICE of Aurobindo's response to Plaintiff's Second Set of Interrogatories re the 667 Patent (No. 4) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth) (Entered: 11/14/2022) (2) |
| Nov 3, 2022 | 37 | NOTICE of Service of Aurobindo's Supplemental Responses and Objections to Novartis's First Set of Interrogatories to Aurobindo (Nos. 1-3), filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth) Modified on 11/3/2022 (nms). (Entered: 11/03/2022) (2) |
| Oct 7, 2022 | 36 | NOTICE OF SERVICE of Novartis's Second Set of Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/07/2022) (10) |
| Sep 12, 2022 | 35 | NOTICE OF SERVICE of Defendants' Joint Initial Invalidity Contentions for the 667 Patent filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Hitch, Cortlan) (Entered: 09/12/2022) (4) |
| Sep 9, 2022 | 34 | NOTICE OF SERVICE of (1) Aurobindo's response to Plaintiffs' First Set of Interrogatories re the 667 Patent (Nos. 1-3); and (2) Aurobindo's response to Plaintiff's First Set of Requests for Production re the 667 Patent (Nos. 1-41) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Hitch, Cortlan) (Entered: 09/09/2022) (2) |
| Sep 7, 2022 | 33 | NOTICE OF SERVICE of (1) Plaintiff's Rule 26(a)(1) Initial Disclosures, and (2) Plaintiff's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/07/2022) (14) |
| Sep 7, 2022 | 32 | NOTICE OF SERVICE of (1) Aurobindo's 26(a) Initial Disclosures for the '918 Patent; (2) Aurobindo's Paragraph 3 Disclosures for the '918 Patent; (3) Aurobindo's 26(a) Initial Disclosures for the '667 Patent and; (4) Aurobindo's Paragraph 3 Disclosures for the '667 Patent filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth) (Entered: 09/07/2022) (3) |
| Aug 29, 2022 | 31 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 08/29/2022) (21) |
| Aug 26, 2022 | 30 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/28/2022 (nms). (Entered: 08/26/2022) (21) |
| Aug 17, 2022 | 29 | Official Transcript of Rule 16 Conference held on 8/3/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/7/2022. Redacted Transcript Deadline set for 9/19/2022. Release of Transcript Restriction set for 11/15/2022. (Triozzi, Heather) (Entered: 08/17/2022) (29) |
| Aug 11, 2022 | 28 | NOTICE OF SERVICE of (1) Novartis's First Set of Requests to Defendants for the Production of Documents and Things and (2) Novartis's First Set of Interrogatories to Defendants (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/11/2022) (13) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 25, 2022 | 27 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Chart for U.S. Patent No. 11,058,667 and Plaintiff's First Supplemental Infringement Chart for U.S. Patent No. 11,096,918 against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 25 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 24 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | 23 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 21 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 20 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 19 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | 18 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 17 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 1, 2022 | 16 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Jan 13, 2022 | 14 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Dorsney, Kenneth) |
| Jan 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [14] MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Leonard P. Stark on 1/13/22. (ntl) |
| Jan 11, 2022 | 13 | Answer to Counterclaim (11) Docket Text: ANSWER to [11] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Dec 21, 2021 | 12 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma USA Inc. filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Dorsney, Kenneth) |
| Dec 21, 2021 | 11 | Answer to Complaint (29) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Aurobindo Pharma USA Inc., Aurobindo Pharma Ltd..(Dorsney, Kenneth) |
| Dec 6, 2021 | 10 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Aurobindo Pharma USA Inc. served on 12/1/2021, answer due 12/22/2021. (Joyce, Alexandra) |
| Dec 6, 2021 | 9 | Exhibit A-B (7) |
| Dec 6, 2021 | 9 | Main Document (2) Docket Text: DECLARATION of Service of Aurobindo Pharma Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 4/8/2022 (nms). |
| Dec 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Dec 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Christina Schwarz and Nicholas N. Kallas for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Nov 30, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [8] MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/30/21. (ntl) |
| Nov 17, 2021 | 8 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a (4) |
| Nov 17, 2021 | 8 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) |
| Oct 6, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Oct 1, 2021 | 1 | Complaint* (1) |
| Oct 1, 2021 | 7 | Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma Ltd. on 10/4/2021. (twk) |
| Oct 1, 2021 | 6 | Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma USA Inc. on 10/4/2021. (twk) |
| Oct 1, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (twk) |
| Oct 1, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (twk) |
| Oct 1, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than August 20, 2021. Date of Expiration of Patent: May 9, 2036. Regulatory Stay Deadline: No Earlier than July 7, 2023 (8 years from date of NDA approval). (twk) |
| Oct 1, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Oct 1, 2021 | 1 | Civil Cover Sheet (2) |
| Oct 1, 2021 | 1 | Exhibit A (16) |
| Oct 1, 2021 | 1 | Main Document (13) Docket Text: COMPLAINT against Aurobindo Pharma USA Inc. and Aurobindo Pharma Ltd. filed against Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3712749.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(twk) |
